casirivimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
primate origin 5455 2415933-42-3

Description:

MoleculeDescription

Molfile

Synonyms:

  • casirivimab
  • REGN10933
  • regen-cov
  • ronapreve
Casirivimab with imdevimab to be administered together is authorized for use under an EUA for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Casirivimab(IgG1kappa) and imdevimab (IgG1lambda) are two recombinant human mAbs which are unmodified in the Fc regions. Casirivimab and imdevimab bind to non-overlapping epitopes of the spike protein receptor binding domain (RBD) of SARS-CoV-2. Casirivimab, imdevimab and casirivimab and imdevimab together blocked RBD binding to the human ACE2 receptor with IC50 values of 56.4 pM, 165 pM and 81.8 pM, respectively.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 12, 2021 EMA ROCHE REGISTRATION GMBH
Nov. 21, 2020 FDA Regeneron Pharmaceuticals, Inc.
July 19, 2021 PMDA CHUGAI PHARMACEUTICAL Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Wrong product administered 124.88 45.87 25 633 6116 63482248
Infusion related reaction 112.46 45.87 53 605 245468 63242896
COVID-19 pneumonia 78.68 45.87 20 638 14189 63474175
Flushing 62.97 45.87 25 633 75062 63413302

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infusion related reaction 125.77 47.77 43 549 53014 34903325
Wrong product administered 99.40 47.77 22 570 5312 34951027
COVID-19 pneumonia 69.78 47.77 21 571 16946 34939393
Hypoxia 48.84 47.77 22 570 55073 34901266

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Wrong product administered 223.69 51.87 47 1292 8965 79734084
Infusion related reaction 222.78 51.87 97 1242 230140 79512909
COVID-19 pneumonia 146.56 51.87 42 1297 28807 79714242
Dyspnoea 82.27 51.87 85 1254 856940 78886109
Hypoxia 81.55 51.87 38 1301 103205 79639844
Oxygen saturation decreased 64.95 51.87 35 1304 129012 79614037
Flushing 62.02 51.87 30 1309 88238 79654811

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J06BD07 ANTIINFECTIVES FOR SYSTEMIC USE
IMMUNE SERA AND IMMUNOGLOBULINS
IMMUNOGLOBULINS
Antiviral monoclonal antibodies
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
COVID-19 indication 840539006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Spike glycoprotein Glycoprotein BINDING AGENT Kd 10.34 DRUG LABEL DRUG LABEL

External reference:

IDSource
D11938 KEGG_DRUG
J0FI6WE1QN UNII
C5422688 UMLSCUI
CHEMBL4650248 ChEMBL_ID
DB15941 DRUGBANK_ID
11861 INN_ID
C000711751 MESH_SUPPLEMENTAL_RECORD_UI
11327 IUPHAR_LIGAND_ID
018563 NDDF
1137366009 SNOMEDCT_US
1162700002 SNOMEDCT_US
4039878 VANDF
2415933-42-3 SECONDARY_CAS_RN
2465242 RXNORM
341252 MMSL
343591 MMSL
39041 MMSL
d09684 MMSL
C000711487 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Casirivimab HUMAN PRESCRIPTION DRUG LABEL 1 61755-024 INJECTION, SOLUTION, CONCENTRATE 1332 mg INTRAVENOUS UNAPPROVED DRUG OTHER 32 sections
Casirivimab HUMAN PRESCRIPTION DRUG LABEL 1 61755-024 INJECTION, SOLUTION, CONCENTRATE 1332 mg INTRAVENOUS UNAPPROVED DRUG OTHER 32 sections
Casirivimab HUMAN PRESCRIPTION DRUG LABEL 1 61755-026 INJECTION, SOLUTION, CONCENTRATE 300 mg INTRAVENOUS UNAPPROVED DRUG OTHER 32 sections
Casirivimab HUMAN PRESCRIPTION DRUG LABEL 1 61755-026 INJECTION, SOLUTION, CONCENTRATE 300 mg INTRAVENOUS UNAPPROVED DRUG OTHER 32 sections
REGEN-COV HUMAN PRESCRIPTION DRUG LABEL 2 61755-039 INJECTION, SOLUTION, CONCENTRATE 600 mg INTRAVENOUS UNAPPROVED DRUG OTHER 32 sections
REGEN-COV HUMAN PRESCRIPTION DRUG LABEL 2 61755-039 INJECTION, SOLUTION, CONCENTRATE 600 mg INTRAVENOUS UNAPPROVED DRUG OTHER 32 sections